Literature DB >> 4376163

Diagnostic difficulties encountered in the myasthenic syndrome sometimes associated with carcinoma.

J C Brown, R J Johns.   

Abstract

Six patients with the physiological features of the myasthenic syndrome associated with carcinoma are presented. The clinical features encountered in this group, including age, mode of onset, and duration of symptom indicate that it may escape detection owing to its resemblance to other neuromuscular disorders. Conventional concentric needle electromyography may lead to the disorder being confused with a myopathy. The association with carcinoma is by no means constant. Clinical and physiological improvement with guanidine is described in each case.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4376163      PMCID: PMC494885          DOI: 10.1136/jnnp.37.11.1214

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  13 in total

1.  The effect of guanidine on neuromuscular transmission.

Authors:  M OTSUKA; M ENDO
Journal:  J Pharmacol Exp Ther       Date:  1960-03       Impact factor: 4.030

2.  Studies in neuromuscular function. I. Introduction and methods.

Authors:  D GROB; A M HARVEY; R J JOHNS
Journal:  Bull Johns Hopkins Hosp       Date:  1956-09

3.  Carcinomatous neuropathy and myopathy a clinical and pathological study.

Authors:  R A HENSON; D S RUSSELL; M WILKINSON
Journal:  Brain       Date:  1954       Impact factor: 13.501

4.  Subacute cerebellar degeneration and Eaton-Lambert syndrome with bronchogenic carcinoma. A case report.

Authors:  E Satoyoshi; H Kowa; N Fukunaga
Journal:  Neurology       Date:  1973-07       Impact factor: 9.910

5.  The Eaton-Lambert syndrome. Report of a case.

Authors:  S J Oh
Journal:  Arch Neurol       Date:  1972-07

6.  Myopathy remitting in pregnancy and responding to high-dosage oestrogen and progestogen therapy.

Authors:  J B Stanton; J A Strong
Journal:  Lancet       Date:  1967-08-05       Impact factor: 79.321

7.  The pseudomyasthenic syndrome of Eaton and Lambert: an electrophysiological study.

Authors:  W W Hofmann; J E Kundin; D F Farrell
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1967-09

8.  Clinical and physiological studies of the effect of guanidine of patients with myasthenia gravis.

Authors:  J C Brown; R J Johns
Journal:  Johns Hopkins Med J       Date:  1969-01

9.  Defects of neuromuscular transmission in syndromes other than myasthenia gravis.

Authors:  E H Lambert
Journal:  Ann N Y Acad Sci       Date:  1966-01-26       Impact factor: 5.691

10.  The nature of the defect in the Eaton-Lambert syndrome.

Authors:  M P McQuillen; R J Johns
Journal:  Neurology       Date:  1967-06       Impact factor: 9.910

View more
  6 in total

1.  Effect of temperature on neuromuscular transmission in the Eaton-Lambert syndrome.

Authors:  C D Ward; N M Murray
Journal:  J Neurol Neurosurg Psychiatry       Date:  1979-03       Impact factor: 10.154

Review 2.  Lambert-Eaton myasthenic syndrome.

Authors:  U Seneviratne; R de Silva
Journal:  Postgrad Med J       Date:  1999-09       Impact factor: 2.401

3.  Anesthetic management of a patient suspected of having Lambert-Eaton syndrome due to an unexpected prolongation of vecuronium.

Authors:  Kouichiro Minami; Takeyoshi Sata; Hiroshi Ishimura; Yuko Tomotari; Akio Shigematsu
Journal:  J Anesth       Date:  1994-12       Impact factor: 2.078

4.  Eaton-Lambert syndrome: a clinical and electrophysiological study of a patient treated with 4-aminopyridine.

Authors:  D B Sanders; Y I Kim; J F Howard; C A Goetsch
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-11       Impact factor: 10.154

Review 5.  Lambert-Eaton myasthenic syndrome.

Authors:  J Newsom-Davis
Journal:  Springer Semin Immunopathol       Date:  1985

6.  The influence of local cooling on neuromuscular transmission in the myasthenic syndrome of Eaton and Lambert.

Authors:  K Ricker; G Hertel; S Stodieck
Journal:  J Neurol       Date:  1977-12-13       Impact factor: 4.849

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.